SGS Increases Biosafety Testing Capacity at Glasgow Facility
SGS has just completed an expansion project at its Glasgow facility, meaning it can provide increased biosafety testing for the biologics, drug development, and cell and gene therapy industries.
The project, which began back in March 2021 and was completed in September 2021, saw the footprint of the Glasgow facility increase by 550m2, meaning the facility now totals 3,100m2 in size and has a staff of 130 employees.
Sixteen BSL-2 laboratories have been added to our Glasgow facility. These laboratories contain a range of equipment, including BSL-2 cabinets, ELISA (enzyme-linked immunosorbent assay) technology, cell culture equipment for virus detection and real-time PCR (polymerase chain reaction) testing equipment.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
May 21st 2025In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.
